Literature DB >> 18185904

Mycophenolate mofetil in the treatment of retroperitoneal fibrosis.

Fareeha Khalil1, M A Mir, Rocco C Venuto.   

Abstract

The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18185904     DOI： 10.1007/s10067-007-0826-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  11 in total

1.  Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids.

Authors:  W Grotz; I von Zedtwitz; M Andre; P Schollmeyer
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

2.  Idiopathic retroperitoneal fibrosis and ankylosing spondylitis. A new case report.

Authors:  A Bezza; A El Maghraoui; M Ghadouane; F Tabache; A Abouzahir; M Abbar; D Ghafir; V Ohayon; M I Archane
Journal:  Joint Bone Spine       Date:  2002-10       Impact factor: 4.929

3.  The association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature.

Authors:  G O Littlejohn; E C Keystone
Journal:  J Rheumatol       Date:  1981 Jul-Aug       Impact factor: 4.666

4.  The localisation of immunoglobulin in chronic periaortitis.

Authors:  D V Parums; D R Chadwick; M J Mitchinson
Journal:  Atherosclerosis       Date:  1986-08       Impact factor: 5.162

5.  Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis.

Authors:  Paul J Scheel; Jonathan Piccini; M Hafizur Rahman; Leo Lawler; Thomas Jarrett
Journal:  J Urol       Date:  2007-05-17       Impact factor: 7.450

6.  Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases.

Authors:  L R Baker; W J Mallinson; M C Gregory; E A Menzies; W R Cattell; H N Whitfield; W F Hendry; J E Wickham; A M Joekes
Journal:  Br J Urol       Date:  1987-12

7.  Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis.

Authors:  A S Scavalli; A Spadaro; V Riccieri; G P Ricciuti; E Taccari; M Marini; A Zoppini
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

8.  [Mycophenolate mofetil combined with steroids: new experiences in the treatment of idiopathic retroperitoneal fibrosis].

Authors:  Katarina Obrencević; Dragan Jovanović; Zoran Kovacević; Rajko Hrvacević; Ljiljana Ignjatović; Mirjana Mijusković
Journal:  Vojnosanit Pregl       Date:  2007-06       Impact factor: 0.168

9.  Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.

Authors:  Fuad S Shihab; William M Bennett; Hong Yi; Seung Ok Choi; Takeshi F Andoh
Journal:  Am J Transplant       Date:  2003-12       Impact factor: 8.086

10.  Periarticular fibrosis associated with idiopathic retroperitoneal fibrosis.

Authors:  E A Ewald; P W Gikas; C W Castor
Journal:  J Rheumatol       Date:  1988-09       Impact factor: 4.666
View more
  1 in total

1.  Medical management of retroperitoneal fibrosis.

Authors:  Paul J Scheel; Stephen M Sozio; Nancy Feeley
Journal:  Trans Am Clin Climatol Assoc       Date:  2012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.